A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS-Reference-Cited by-同舟云学术

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Published:2014-08-15 Issue:5-6 Volume:15 Page:406-413
ISSN:2167-8421
Container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
language:en
Short-container-title:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Author:

Bozik Michael E.,Mitsumoto Hiroshi,Brooks Benjamin R.,Rudnicki Stacy A.,Moore Dan H.,Zhang Bing,Ludolph Albert,Cudkowicz Merit E.,van den Berg Leonard H.,Mather James,Petzinger Thomas,Archibald Donald

Publisher

Informa UK Limited

Subject

Neurology (clinical),Neurology

Link

http://www.tandfonline.com/doi/pdf/10.3109/21678421.2014.943672

Reference34 articles.

1. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

2. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

3. Prognostic factors in ALS: A critical review

4. Prognosis in amyotrophic lateral sclerosis: A population-based study

5. Prognostic categories for amyotrophic lateral sclerosis

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2024-02-07

2. Biomarkers: Role and Scope in Neurological Disorders;Neurochemical Research;2023-02-16

3. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy;Journal of Human Genetics;2022-06-13

4. Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2020-06-22

5. Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis;Expert Opinion on Pharmacotherapy;2020-04-03